Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.
about
Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma.TEX101, a glycoprotein essential for sperm fertility, is required for stable expression of Ly6k on testicular germ cells.The prevalence and expression pattern of melanoma-associated antigen 1 in esophageal squamous cell carcinoma: a historical cohort studyTumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the artCurrent status of cancer immunotherapyIdentification of immunogenic LY6K long peptide encompassing both CD4(+) and CD8(+) T-cell epitopes and eliciting CD4(+) T-cell immunity in patients with malignant diseasePhase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancerPhase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients.Immunotherapy for lung cancers.Therapeutic cancer vaccines: are we there yet?Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses.Therapeutic vaccines for gastrointestinal cancers.Identification of immunogenic MAGED4B peptides for vaccine development in oral cancer immunotherapyMulticenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer.Possibility of the use of public microarray database for identifying significant genes associated with oral squamous cell carcinomaTrial watch: Peptide vaccines in cancer therapyImmunotherapy for gastrointestinal malignancies.Immunogenic tumor cell death induced by chemoradiotherapy in a clinical settingInsulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer.Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancerImmunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation.Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance.Immunological suppression of head and neck carcinoma by dendritic cell tumor fusion vaccine.Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer.A systematic approach to the development of novel therapeutics for lung cancer using genomic analyses.Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine?Characterization of an Opa interacting protein 5 involved in lung and esophageal carcinogenesis.ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW.Promising immunotherapies for esophageal cancer.Emerging immunotherapy for the treatment of esophageal cancer.Esophageal cancer: The latest on chemoprevention and state of the art therapies.Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapyIdentification of HLA-A24-restricted novel T Cell epitope peptides derived from P-cadherin and kinesin family member 20ALY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling.Development of Peptide Vaccines in Dengue.Quantitative analysis and clonal characterization of T-cell receptor β repertoires in patients with advanced non-small cell lung cancer treated with cancer vaccine.Threonine and tyrosine kinase may serve as a prognostic biomarker for gallbladder cancer.In silico prediction of B cell epitopes of the extracellular domain of insulin-like growth factor-1 receptor.An oncofetal antigen, IMP-3-derived long peptides induce immune responses of both helper T cells and CTLs.
P2860
Q33274978-BDC49D39-A798-4E11-902F-F2D2525D0E6BQ33289334-BD5329F3-FC7A-49A8-88B2-10741779BD8DQ33620367-CDB86AC3-4AC0-4594-BD4E-3CB39AD9E169Q33907628-F8BAD828-53A0-4AEF-A4C4-1E655BD02820Q33955720-E696E573-4145-4829-BB2F-70C7C00B3273Q34372937-1D35B69F-F83A-465D-9F14-0ABF561B4314Q34478149-08C9E130-CD16-4195-9B2F-1B92FDC48CF0Q34522972-0D8F7C3C-950E-4D92-94FF-238280FD1F03Q34557611-25A233B0-9494-448E-B87F-3FF906137C9FQ34786691-C5691ACC-00B5-435E-B80C-E64E96037034Q35569528-EA8BCFBD-1DD0-464F-B61D-C9622BC18DE2Q35691248-CB4A36AD-9889-42FC-8554-4F422D13D57EQ35896241-861851B6-9D79-4D0C-8749-B42F3D28236CQ36112645-FDE02AD6-EBAB-4FA1-AA16-4C3DDC41679EQ36230515-5ABE7638-CE44-4E56-9D23-1BAE1E14578EQ36330529-B31CAE44-F44E-4350-AC78-EFB0B27BDFABQ36476100-2DE52DF8-9D68-4F6B-8E25-29620A5B39B8Q36602174-8AEA9CA7-625F-45F7-BD08-5EE6F7352FE3Q36643618-AA386EB5-0906-44A2-B175-DA9C2A8D1500Q36733283-93E45DB5-A490-46DA-8794-4C636AE4D9CAQ36803441-2D4075E6-DE02-4DAE-A7D4-6E71B8A00AC9Q36985164-4BBEB4CD-FB76-4F69-AE4B-EBD24AD6C05DQ37012226-CFEFA7B7-1E37-4744-9C2D-33D268243EE4Q37325047-1271AFA8-05DB-481A-8A76-FA82F2FDCA58Q37591955-930E0472-600F-44CA-A901-33B84B68736DQ38105238-01F33FCC-D1DC-4A45-B3E1-1E579C8F6FEDQ38286381-757631C0-40B2-4269-B3B1-E9B74806C70EQ38406799-88A2A6F8-AAD2-41B3-832E-89A6E1225595Q38541959-724B547D-A067-4C2D-ADFC-C7685C9D43B8Q38736566-F18BF38D-DDF3-4C99-B55D-6E11337B7FEDQ38763851-A4EFADE9-6F4D-45E1-B37C-83EB159D263EQ38938101-73899D58-D17B-4EA0-B947-8B0EB42E1B81Q38949770-495874C5-4018-4EB8-A8A2-8EAD4B0C48ACQ39317151-2FF52E50-E7D7-4E3D-8BFF-7B96AFFC6D36Q39633864-11B2EAAD-A821-4330-8320-AE3A5CFECD69Q40038715-3F95A1FE-58AB-4516-8790-9C82A42C58D5Q40978230-B38367A6-CE56-4D0B-AD1E-0FDEB2505E70Q41505635-A78B9B27-587C-4B60-A8C1-E7CFECF2021BQ41838419-6AFECFF7-8689-4888-BFC3-33A071CC7525Q42427592-5AFA9EFB-B7AF-417D-ADD6-31B064CF1CA8
P2860
Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Vaccination with multiple pept ...... in advanced esophageal cancer.
@en
Vaccination with multiple pept ...... in advanced esophageal cancer.
@nl
type
label
Vaccination with multiple pept ...... in advanced esophageal cancer.
@en
Vaccination with multiple pept ...... in advanced esophageal cancer.
@nl
prefLabel
Vaccination with multiple pept ...... in advanced esophageal cancer.
@en
Vaccination with multiple pept ...... in advanced esophageal cancer.
@nl
P2093
P1433
P1476
Vaccination with multiple pept ...... in advanced esophageal cancer.
@en
P2093
Atsushi Takano
Hideki Fujii
Ken Masuda
Koji Yoshida
Takuya Tsunoda
Yataro Daigo
Yoshihiko Kawaguchi
Yoshiki Mizukami
Yusuke Nakamura
P304
P356
10.1111/J.1349-7006.2009.01200.X
P577
2009-05-14T00:00:00Z